Tarceva
- Scientific Information
Scientific Information
Erlotinib clinical trials
OPTIMAL phase III trial
- OPTIMAL: summary of safety data

OPTIMAL phase III trial

PFS was significantly longer in erlotinib-treated Chinese patients with EGFR Mut+ NSCLC compared with that of patients treated with standard chemotherapy. Erlotinib was also better tolerated.^1,2

Study design and endpoints¹

OPTIMAL was a randomised phase III trial that took place across 22 centres in China.
The trial compared erlotinib versus standard chemotherapy as first-line treatment for EGFR Mut+ NSCLC.

ECOG PS (Eastern Co-operative Oncology Group performance status)

Key Results

Efficacy²

Patients receiving erlotinib had longer PFS than patients receiving chemotherapy.

Safety¹

Patients treated with erlotinib experienced fewer treatment related severe AEs, fewer grade 3/4 AEs and fewer dose reductions due to AEs than patients treated with chemotherapy.

Please click here for further safety data

OPTIMAL: summary of safety data¹
OPTIMAL: most common adverse events reported in 3% of patients or more in either treatment group¹

Reference

Zhou C, et al. Lancet Oncol 2011; 12:735–42;
Chen G, et al. Ann Oncol 2013; 24:1615–22

OPTIMAL phase III trial

PFS was significantly longer in erlotinib-treated Chinese patients with EGFR Mut+ NSCLC compared with that of patients treated with standard chemotherapy. Erlotinib was also better tolerated.1,2

Key Results

PFS was significantly longer in erlotinib-treated Chinese patients with EGFR Mut+ NSCLC compared with that of patients treated with standard chemotherapy. Erlotinib was also better tolerated.^1,2